Prof. M Llovet has published 369 manuscripts (h-index:157, citations:152,040), and has been awarded by Clarivate Analytics as a top 1% cited investigator in all years from 2014 to 2024. Top 0.01% investigator according to Stanford mètrics.
His research has been focused on clinical and translational studies in liver cancer for the last 30 years, with the following achievements: a) Leading author/ Principal investigator of RCT leading to standard of care therapies for hepatocellular carcinoma (HCC), such as systemic treatment (sorafenib), chemoembolization and the combination of lenvatinib plus pembrolizumab plus TACE, in intermediate HCC. In addition, he led proposals of molecular and immune classification of HCC (2008,2017, 2023) and established an imaging criteria for assessment of response to therapies (modified RECIST). He has participated/led 14 Clinical Practice Guidelines form AASLD; EASL, ESMO and ILCA.
In terms of participation in scientific institutions, he is Editor in Chief of J HEP Reports; Founder, Secretary and President of the International Liver Cancer Association (ILCA); Founder and Director of the Mount Sinai Liver Cancer Program (2005-2023), the first program on liver cancer recognized by NCI in the USA;); Principal investigator of research funding with > 120 competitive grants, including coordinator of 2 European Union FP7 and Horizon Europe grants and 2 NIH-RO1.
